John B.A.G. Haanen
Leiden University · 1,032 works · 101,616 citations · h-index 112
Top works
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression.
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
- Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
- Selection of a human T helper type 1-like T cell subset by mycobacteria.
- Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
- Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
- High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
- Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
- Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers
- Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma